The U.S. Food and Drug Administration (FDA) has issued its recommendations to vaccine makers on which virus strains to select when manufacturing influenza (flu) vaccines for the 2025-2026 U.S. flu ...
In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...
The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...
Expected to enhance global innovator flexibility with biologics drug substance facility in Baltimore BANGALORE, India, March ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
Our team’s strong focus and execution over the last twelve months lay the groundwork for a potential breakthrough year for iTeos in 2025. As we advance multiple trials evaluating belrestotug + ...
Multinational pharmaceutical company GSK’s commitment to invest up to $800 million in its facility near Marietta may have ...
Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...
Former Barrow and Furness MP Simon Fell chaired a taskforce which developed a vision for Ulverston Life Science and Advanced Manufacturing Park on the former GSK site, which had been tipped to create ...
Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...
LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback